Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Metastatic Castration-Resistant Prostate Cancer Pipeline Report to explore emerging therapies, key Metastatic Castration-Resistant Prostate Cancer Companies, and future Metastatic Castration-Resistant Prostate Cancer treatment landscapes @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
In August 2025, Novartis Pharmaceuticals announced a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
announced a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated. In August 2025, Pfizer announced a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
announced a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve. In August 2025, Amgen conducted a study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
conducted a study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]). In August 2025, Merck Sharp & Dohme LLC announced a study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort.
announced a study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort. In August 2025, AstraZeneca organized a study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
organized a study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations. DelveInsight's Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
The leading Metastatic Castration-Resistant Prostate Cancer Companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
and others. Promising Metastatic Castration-Resistant Prostate Cancer Therapies such as JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
Discover how the Metastatic Castration-Resistant Prostate Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Studies
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
The Metastatic Castration-Resistant Prostate Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Castration-Resistant Prostate Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Castration-Resistant Prostate Cancer Treatment.
Metastatic Castration-Resistant Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Castration-Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market.
Get a detailed analysis of the latest innovations in the Metastatic Castration-Resistant Prostate Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Metastatic Castration-Resistant Prostate Cancer Unmet Needs
Metastatic Castration-Resistant Prostate Cancer Companies
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Oral
Intravenous
Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Metastatic Castration-Resistant Prostate Cancer Therapies and key Cervical Cancer Developments @ Metastatic Castration-Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
Coverage- Global
Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen , and others.
, and others. Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
and others. Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Metastatic Castration-Resistant Prostate Cancer drug development? Find out in DelveInsight's exclusive Metastatic Castration-Resistant Prostate Cancer Pipeline Report—access it now! @ Metastatic Castration-Resistant Prostate Cancer Emerging Drugs and Major Companies
Table of Contents
Introduction Executive Summary Metastatic Castration Resistant Prostate Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Metastatic Castration Resistant Prostate Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Rucaparib: Clovis Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Surface Oncology: SRF 617 Drug profiles in the detailed report….. Early Stage Products (Phase I/II) REGN 4336: Regeneron Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) HP 518: Hinova Pharmaceuticals Drug profiles in the detailed report….. Inactive Products Metastatic Castration Resistant Prostate cancer Key Companies Metastatic Castration Resistant Prostate cancer Key Products Metastatic Castration Resistant Prostate cancer- Unmet Needs Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion Metastatic Castration Resistant Prostate cancer Analyst Views Metastatic Castration Resistant Prostate cancer Key Companies Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name:DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Royal Gold Announces Fourth Quarter Dividend
Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, 'Royal Gold' or the 'Company') announced today that its Board of Directors has declared its fourth quarter dividend of $0.45 per share of common stock. The dividend is payable on Friday, October 17, 2025, to shareholders of record at the close of business on Friday, October 3, 2025. Corporate Profile Royal Gold is a high margin, mid-capitalization company that generates strong cash flows from a large and well-diversified portfolio of precious metal streams, royalties and similar production-based interests located in mining-friendly jurisdictions. Royal Gold shares trade under the symbol 'RGLD' and provide growth, value and income investors with exposure to the metals and mining industry. The Company's website is located at
Globe and Mail
3 hours ago
- Globe and Mail
Automotive Bearings Market driven by the Technological Advancements and EVs rising demand
The Global Automotive Bearings Market is estimated to reach USD 61915.20 million by 2032 with a Compound Annual Growth Rate (CAGR) of 6.5 % from 2026 to 2032. Primary driving factors include the Rise of EV production, Material & Design Technology Advancements. The Global Automotive Bearings Market is estimated to reach USD 61915.20 million by 2032 with a Compound Annual Growth Rate (CAGR) of 6.5 % from 2026 to 2032. Primary driving factors include the Rise of EV production, Material & Design Technology Advancements. The latest premium report by Profshare Market Research ' Automotive Bearings Market by Product Types ( Ball Bearings, Roller Bearings, Others) by Applications ( Passenger Vehicles, Commercial Vehicles, Two Wheelers) Industry Analysis, Volume, Market Shares, Challenges, Trends, Strategies & Forecast 2026-2032, Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa)' Automotive Bearings Market Segmentation: By Bearing types, the Ball Bearings segment is projected to show the highest CAGR during the forecast period. Ball Bearings, Roller Bearings, and Others are primary food types, and the Ball Bearings segment leads the market due to the high usage of Ball bearings in passenger cars. Passenger cars dominate the automotive market by volume, and hence, drive the demand for Automotive Bearings. Also, high-speed, low-friction ball bearings are ideal, which fuels the segment's growth. Roller bearings are more common in trucks, buses, and off-road vehicles, and as their volume is less compared to Passenger vehicles, the Roller Bearings segment revenue is relatively less than that of Ball Bearings. Access the Sample Report: By Application, the Passenger Vehicles application accounts for the largest share in the Automotive Bearings Market. The Passenger Vehicles application leads the market in terms of revenue generation and growth rate. Global production of passenger cars is growing faster compared to Heavy commercial vehicles, and hence the application of Automotive Bearings in Passenger cars generates the highest revenue. The demand for Automotive Bearings in Commercial Vehicles is likely to rise between 2026 and 2032 at a modest CAGR, mainly due to higher sales of electric commercial vehicles and Aftermarket sales. The Two-wheeler Automotive Bearings application is also on the rise, especially in the developing economies. The Asia-Pacific region leads the Automotive Bearings Market and is projected to grow at the highest Compound Annual Growth Rate (CAGR) between 2026 and 2032 Regional outlook focuses on the market revenue and latest developments in the various regions like North America, Europe, Asia-Pacific, the Middle East, South America and Africa. According to the latest study by Profshare Market Research on the Automotive Bearings Market, the Asia-Pacific region holds the largest market share and continues to do so due to high vehicle production and a large consumer base for Passenger Vehicles, Commercial Vehicles, and two-wheelers. North America, Europe, the Middle East, South America and Africa regions are also estimated to show a strong growth rate during the forecast period. Major Key Players in the Automotive Bearings Market: NTN NSK SKF Schaeffler ILJIN JTEKT FKG Automotive Bearings Market Report Key Takeaways The Automotive Bearings Market is projected to reach USD 61915.20 million by the end of 2032, with an approximate CAGR of 6.5 % between 2026 and 2032. By market dynamics, the Rise of EVs Production, Material & Design Technology Advancements and Government Initiatives are fuelling the demand for the Automotive Bearings Market. Based on the Bearing types, the Ball Bearings segment is projected to grow at the highest CAGR during the forecast period, primarily due to the high usage of Ball bearings in passenger cars. The application market study shows that the Passenger Vehicles application dominates the market, as production of Passenger cars is growing faster compared to Heavy commercial vehicles. Based on the regional analysis, the Asia-Pacific region is estimated to hold the largest market share due to high vehicle production and a large consumer base. By competitive Analysis, the traditional automotive bearings market is saturated, but next-gen EV bearings, smart/sensorized solutions, and two-wheeler markets hold greater potential in the upcoming years. Industry Top Reports: Automotive Drive Shafts Market: Automotive Drive Shafts Market Report by Product Type (Hotchkiss Drive Shaft, Flexible Drive Shaft, Torque Tube Drive Shaft ) by Application /End User (Passenger Cars, Light Commercial Vehicles, Heavy Commercial Vehicles ), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032. Electric Utility Vehicles Market: Electric Utility Vehicles Market by Product Type (Lead Acid Type and Lithium Ion Type) by Application (Farm, Large Venues and Hunting Trips), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032. Electric Vehicles (EVs) Market: Electric Vehicles (EVs) Market by Vehicle Type( Hybrid Electric Vehicle (HEV), Battery Electric Vehicle (BEV) and Plugin Hybrid Electric Vehicle (PHEV)) by Application / End User( Passenger Cars, Buses, Commercial Vehicles), Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032. Electric Scooters Market: Power Type (Charging, Battery swapping, Hybrid, Fuel cell) by Battery Type (Li-Ion, Sealed Lead Acid) , Regional Outlook ( North America, Europe, Asia-Pacific, Middle-East, South America, Africa) and Forecast 2032. About Proshare Market Research Profshare Market Research is a leading Market Research & Consulting Organization that turns data into decisions and insights into impact. We are a global market intelligence firm committed to delivering actionable, accurate, and forward-looking market research that empowers businesses to stay ahead in an ever-changing marketplace. From emerging startups to Fortune 500 companies, our clients trust us to decode complexity, spot opportunities, and reduce risk. With a robust network of data analysts and industry experts, we provide customized market research solutions that align with clients' unique goals. Media Contact Company Name: Profshare Market Research Contact Person: Rajeswari Deep Email: Send Email Phone: + 1 628 8006808 Address: 1207 Delaware Ave. Suite 4458 DE 19806 City: Wilmington State: Delaware Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Diabetic Retinopathy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Diabetic Retinopathy Pipeline Insights 2025 ' report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook Key Takeaways from the Diabetic Retinopathy Pipeline Report On August 18, 2025 (Monday), findings published online in JAMA Ophthalmology (August 14 edition) revealed that semaglutide therapy in adults with diabetes does not raise the risk of developing eye disorders or diabetic retinopathy. On August 15, 2025, Eyepoint Pharmaceuticals Inc. carried out a randomized, double-masked clinical trial assessing the ocular safety and efficacy of two different doses of the EYP-1901 IVT insert, compared with a sham treatment. On August 18, 2025, Genentech Inc. initiated a clinical trial designed to investigate both ocular and systemic safety, tolerability, and efficacy of RO7446603 in patients with diabetic macular edema (DME). The study includes two main parts: Phase I (Parts 1–4), which examined the safety of single and multiple intravitreal (IVT) doses as monotherapy or in combination with IVT aflibercept or IVT faricimab (administered separately), and Phase II (Part 5) for further evaluation. DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment. The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment Diabetic Retinopathy Emerging Drugs Profile Tarcocimab tedromer: Kodiak Sciences Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate (""ABC"") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy. OTT166: Ocuterra Therapeutics Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy. APX3330: Apexian Pharmaceuticals APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy. OTX-TKI: Ocular Therapeutix OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy. The Diabetic Retinopathy Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment. Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs Diabetic Retinopathy Companies Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives Scope of the Diabetic Retinopathy Pipeline Report Coverage- Global Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective Table of Content Introduction Executive Summary Diabetic Retinopathy: Overview Pipeline Therapeutics Therapeutic Assessment Diabetic Retinopathy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) KSI-301: Kodiak Sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) RGX 314: Regenxbio Inc Drug profiles in the detailed report….. Early Stage Products (Phase I) OTX-TKI: Ocular Therapeutix Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetic Retinopathy Key Companies Diabetic Retinopathy Key Products Diabetic Retinopathy- Unmet Needs Diabetic Retinopathy- Market Drivers and Barriers Diabetic Retinopathy- Future Perspectives and Conclusion Diabetic Retinopathy Analyst Views Diabetic Retinopathy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
